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Background: The identiﬁcation of patients at risk for worse outcome is still a challenge. We hypothesized that
cystatin C, a marker of renal function, and neutrophil gelatinase-associated lipocalin (NGAL), a marker of
acute renal injury, would have a role in the prognostic stratiﬁcation of these patients.
Methods: We prospectively evaluated 121 patients admitted for acute HF. Serum NGAL and cystatin C levels
were measured on the ﬁrst morning after admission. The outcome measures used were the occurrence of
death from all causes, and the combined endpoint deﬁned as the ﬁrst occurrence of either death or hospital
admission. Patients were followed for up to 3 months.
Results: The variables associated with a higher occurrence of death in a univariate approach were older age
and higher levels of BNP, cystatin C and NGAL, and those associated with the occurrence of the combined
endpoint were older age, Diabetes mellitus, lower GFR, type 1 cardio-renal syndrome, BNP, cystatin C and
NGAL. BNP and NGAL remained independent predictors of the occurrence of both all-cause death and the
combined endpoint. NGAL levels in the 75th percentile (N167.5 ng/mL) were associated with a 2.7-fold
increase in the risk of death and a 2.9-fold increase in the risk of the ﬁrst occurrence of either death or
hospitalization.
Conclusions: Serum NGAL, a marker of acute renal injury, is an independent predictor of worse short term
prognosis in patients with acute HF. This suggests a role of renal damage, apart from renal function, in the
prognosis of these patients.
© 2011 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Acute heart failure (HF) is the most common cause of hospital
admission in persons older than 65 years [1]. The prognosis of patients
admitted for acute HF is dismal, with a mortality rate of 6,7% during
hospitalization and 13,5% at 3 months [2,3]. The re-hospitalization
rate remains very high, with 24% at 3 months and in the range of 30%
to 50% during the ﬁrst year [3,4]. The identiﬁcation of patients at high
risk of an adverse outcome is still a challenge to clinicians. A variety of
predictors of ominous prognosis have been identiﬁed. Eleven to forty
percent of the patients hospitalized for acute decompensated HF
develop WRF during hospital stay [5] and WRF has been reported tonal function; NGAL, neutrophil
n rate.
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Ltd. All rights reserved.be associated with higher in-hospital mortality, increased all-cause
re-hospitalization rates and longer duration of hospital stay [6–9].
Cystatin C is a cysteine protease inhibitor synthesized by nucleated
cells that is freely ﬁltered in the glomerulus, completely reabsorbed in
the convoluted proximal tubule, and is not secreted. Cystatin C levels
are not affected by sex, age, race, or muscle mass. Previous reports
suggested that cystatin C can have a role in prognosis stratiﬁcation of
acute HF patients [10–12].
Neutrophil gelatinase-associated lipocalin (NGAL) is a glycopro-
tein synthesized in the bone marrow during granulocyte maturation.
Granulocytes, epithelial cells, renal tubular cells, and hepatocytes
release NGAL during injury, and its levels are signiﬁcantly elevated in
epithelial damage [13–15]. Several reports have suggested that NGAL
levels (both urinary and serum) are elevated in patients with acute
kidney injury and type 1 cardio-renal syndrome and this rise in NGAL
levels is known to precede the plasma creatinine increase [16–20].We
have previously reported that a single NGAL measurement indepen-
dently predicts the development of type 1 cardio-renal syndrome in
acutely decompensated HF patients, suggesting that it might be a
useful biomarker in the early recognition of these patients [21].
Table 1
Baseline characteristics of patients as a function of death, and variables associated with all-cause death.
Total
n=120
Death p HR (95% CI) p
value
Yes (n=27) No (n=93)
Age (years), media (SD); per year 75.2 (±12.6) 82.6 (±10.3) 73.0 (±12.4) b0.001 1.08 (1.04–1.12) b0.001
Male sex, n (%) 61 (50.8) 12 (44.4) 49 (52.7) 0.59 0.79 (0.37–1.69) 0.55
Diabetes mellitus, n (%) 30 (25.0) 6 (22.2) 24 (25.8) 0.90 0.87 (0.35–2.16) 0.76
LVEF (%), median (IQR); per 1% 35 (25–45) 35 (29–46) 35 (24–45) 0.59 1.01 (0.97–1.04) 0.70
LVEFb45% (vs. HFPEF), n (%) 80 (67.2) 18 (69.2) 62 (66.7) 0.99 1.16 (0.51–2.68) 0.72
NYHA IV (vs. III), n (%) 80 (66.7) 21 (77.8) 59 (63.4) 0.25 1.93 (0.78–4.79) 0.16
Systolic blood pressure (mm Hg), media (SD); per mm Hg 123 (±28) 114 (±21) 125 (±29) 0.06 0.99 (0.97–1.00) 0.07
Heart rate (bpm), media (SD); per bpm 85 (±20) 85 (±17) 85 (±21) 0.82 1.00 (0.98–1.02) 0.86
Diuretic at admission, n (%) 106 (88.3) 26 (96.3) 80 (86.0) 0.19 3.79 (0.51–27.94) 0.19
Diuretic dose at admission (mg/day), median (IQR); per mg/day 80 (60–100) 80 (60–100) 80 (60–100) 0.42 1.00 (0.99–1.02) 0.40
ACEi or ARB, n (%) 81 (67.5) 17 (63.0) 64 (68.8) 0.74 0.82 (0.38–1.80) 0.62
Beta-blocker, n (%) 61 (50.8) 12 (44.4) 49 (52.7) 0.59 0.76 (0.36–1.63) 0.48
GFR (mL/min per 1.73 m2), median (IQR); per mL/min 40.0 (±16.5) 36.6 (±15.4) 41.3 (±16.7) 0.20 0.98 (0.96–1.01) 0.16
CRS1, n (%) 22 (18.3) 8 (29.6) 14 (15.1) 0.15 2.23 (0.98–5.09) 0.06
BNP (pg/mL), median (IQR); per 100 pg/mL 1594 (773.0–2702.0) 2496 (995.0–3785.0) 1368 (689.4–2285.5) 0.004 1.18 (1.08–1.30) b0.001
Cystatin C (mg/L), media (SD); 75th percentile vs. others 1.70 (0.79) 2.00 (0.96) 1.59 (0.69) 0.02 1.76 (1.16–2.66) 0.008
NGAL (ng/mL), median (IQR); 75th percentile vs. others 95.0 (62.0–167.5) 98.0 (77.0–213.0) 91.0 (60.0–147.0) 0.08 1.04 (1.02–1.06) b0.001
Abbreviations: ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin-receptor blocker; BNP, B-type natriuretic peptide; bpm, beats per minute; CI, conﬁdence interval;
GFR, glomerular ﬁltration rate; CRS1, type 1 cardio-renal syndrome; HR, hazard ratio; HFPEF, heart failure with preserved ejection fraction; IQR, interquartile range; LVEF, left
ventricular ejection fraction; NGAL, neutrophil gelatinase-associated lipocalin; NYHA, New York Heart Association; SD, standard deviation.
52 M. Alvelos et al. / International Journal of Cardiology 165 (2013) 51–55There is an increasing body of evidence supporting the prognostic
impact of several markers of tubulo-interstitial damage, including
NGAL, in various renal disorders [14,22–24]. In HF, contrariwise, the
prognostic value of these markers has not been well established. In a
recent study, both urinary kidney injury molecule-1 and N-acetyl-
β-(D)-glucosaminidase, but not NGAL, showed to add prognostic
information to glomerular ﬁltration rate (GFR) in chronic HF patients
[25], suggesting an important role for tubular damage in cardio-renal
interaction in HF. Recently, higher serum NGAL levels were reported
to be associated with poorer 2-year survival in a chronic HF
population [26].
We aimed to evaluate the short term prognostic signiﬁcance of
biomarkers of renal function and injury in acute HF patients.
2. Materials and methods
2.1. Study sample
We prospectively studied 121 patients admitted to our Internal Medicine
Department between May and November 2009 with the diagnosis of acute HF. Patients
were eligible whether acute HFwas de novo or an exacerbation of chronic HF symptomsTable 2
Baseline characteristics of patients as a function of death or hospitalization, and variables a
Deat
Yes (n=53)
Age (years), media (SD); per year 77.8 (±12.0)
Male sex, n (%) 27 (50.9)
Diabetes mellitus, n (%) 18 (34)
LVEF (%), median (IQR); per 1% 38 (27–45)
LVEFb45% (vs. HFPEF), n (%) 35 (67.3)
NYHA IV (vs. III), n (%) 38 (71.7)
Systolic blood pressure (mm Hg), media (SD); per mm Hg 121 (±26)
Heart rate (bpm), media (SD); per bpm 83 (±18)
Diuretic at admission, n (%) 50 (94.3)
Diuretic dose at admission (mg/day), median (IQR); per mg/day 80 (60–100)
ACEi or ARB, n (%) 35 (66.0)
Beta-blocker, n (%) 23 (43.4)
GFR (mL/min per 1.73 m2), median (IQR); per mL/min 35.7 (±15.4)
CRS1, n (%) 14 (26.4)
BNP (pg/mL), median (IQR); per 100 pg/mL 1797 (916.5–323
Cystatin C (mg/L), media (SD); 75th percentile vs. others 1.91 (0.84)
NGAL (ng/mL), median (IQR); 75th percentile vs. others 102.0 (76.0–202.
Abbreviations: ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin-receptor b
GFR, glomerular ﬁltration rate; CRS1, type 1 cardio-renal syndrome; HR, hazard ratio; HF
ventricular ejection fraction; NGAL, neutrophil gelatinase-associated lipocalin; NYHA, Newwith an increase in at least one New York Heart Association class. HF diagnosis was
based on the European Society of Cardiology criteria. Patients with an acute coronary
syndrome and patients on chronic renal function replacement therapy were excluded.
The study protocol conformed the Declaration of Helsinki, local ethics committee
approved the study and patients gave informed consent.
2.2. Study design
Fasting venous blood samples were collected between 8:00 and 9:00a.m. on the
ﬁrst morning after admission. NGAL and cystatin C levels were measured on the ﬁrst
morning after admission. Specimens were centrifuged for 10 min at 3000 ×gwithin 2 h
after laboratory arrival. Analytical parameters were measured at the Hospital de São
João Clinical Pathology Department. NGAL measurement was made with the Triage
NGAL test system using EDTA-anticoagulated whole blood. This test system is a rapid,
point-of-care ﬂuorescence detection immunoassay using the Triage meter (Biosite,
Quilaban, Lisboa, Portugal). Several drops of blood are added to the sample port in the
device. After addition of the sample, the blood cells are separated from the plasma using
a ﬁlter contained in the test device. The results are displayed in approximately 15 min.
The manufacturer provided the calibration curve. For each 24 patient samples in which
NGAL was determined, one control was performed. The lowest detectable concentra-
tion is 60 ng/mL, and the test has been demonstrated to be linear from 60 to
1300 ng/mL NGAL (which is considered the measurable range). We found a within-run
precision of 19.3% for a sample with an average 132 ng/mL. Serum cystatin C was
assayed using a particle-enhanced immunonephelometric assay (N Latex Cystatin C,ssociated with death or hospitalization.
h or hospitalization p HR (95% CI) p
value
No (n=67)
73.1 (±12.8) 0.04 1.03 (1.00–1.05) 0.04
34 (50.7) 1.00 1.05 (0.61–1.80) 0.86
12 (17.9) 0.07 2.00 (1.13–3.54) 0.02
35 (23–45) 0.42 1.01 (0.98–1.03) 0.54
45 (67.2) 1.00 1.03 (0.58–1.83) 0.93
42 (62.7) 0.40 1.43 (0.79–2.60) 0.24
124 (±29) 0.51 1.00 (0.98–1.01) 0.84
87 (±22) 0.27 0.99 (0.98–1.01) 0.29
56 (83.6) 0.09 2.75 (0.86–8.83) 0.09
80 (60–100) 0.40 1.00 (1.00–1.01) 0.29
46 (68.7) 0.91 0.95 (0.54–1.68) 0.86
38 (56.7) 0.21 0.68 (0.39–1.16) 0.16
43.8 (±16.6) 0.008 0.98 (0.96–0.99) 0.006
8 (11.9) 0.07 1.99 (1.08–3.67) 0.03
3.0) 1277 (626.0–2268.0) 0.04 1.12 (1.04–1.21) 0.005
1.50 (0.66) 0.004 1.66 (1.22–2.26) 0.001
0) 84.0 (60.0–139.0) 0.02 1.04 (1.02–1.05) b0.001
locker; BNP, B-type natriuretic peptide; bpm, beats per minute; CI, conﬁdence interval;
PEF, heart failure with preserved ejection fraction; IQR, interquartile range; LVEF, left
York Heart Association; SD, standard deviation.
Fig. 1. Kaplan–Meier estimates of survival and hospitalization-free survival according to serum NGAL levels. Patients in the highest NGAL quartile have a signiﬁcantly worse short
term prognosis than the ones in the other quartiles.
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0.05 mg/L, and the within-run and the run-to-run variation was b5%. Plasma B-type
natriuretic peptide was measured using an Architect i2000 automated analyzer
(Abbott, Lisboa, Portugal). Serum creatinine, urea and albumin were measured using
conventional methods with an Olympus AU5400 automated clinical chemistry
analyzer. (Beckman-Coulter, Izasa, Porto, Portugal). Blood counts were obtained
using an automated blood counter (Sysmex XE-5000; Emílio de Azevedo Campos,
Porto, Portugal). GFR was estimated according to the Modiﬁcation of Diet in Renal
Disease (MDRD) formula: GFR=170×[PCr]−0.999×[Age]−0.176×[PU]−0.170×[Albu-
min]+0.318×[0.762 if female]×[1.180 if black] [27–29]. All patients performed an
echocardiogram and the left ventricular ejection fraction was determined using the
modiﬁed Simpson method. Left ventricular systolic function was considered preserved
if the left ventricular ejection fraction was ≥45%. Patients received standard treatment
according to the attending physicians. Physicians were blinded to NGAL and cystatin C
levels. Type 1 cardio-renal syndrome was deﬁned as an increase in the creatinine level
of at least 0.3 mg/dL or 50% of basal creatinine during hospitalization.
The outcome measures used to determine the prognostic importance of serum
NGAL and cystatin C were the occurrence of death from all causes, and the combined
endpoint deﬁned as the ﬁrst occurrence of either death or hospital admission.
Information about the outcomes was obtained searching on our hospital records and by
telephone contact with the patients. Patients were followed for up to 3 months after the
ﬁrst day of hospitalization. One patient was lost to follow-up.
2.3. Statistical analysis
Numerical variables are presented as mean (standard deviation) if normally
distributed or median (interquartile range) if non-normally distributed. Categorical
variables are presented as count (percent). Patients who developed the study outcomes
and those who did not were compared: the χ2 test was used to compare categorical
variables, a two independent-sample t test was used to compare normally distributed
variables, and the Mann–Whitney U test was used for skewed variables. We used
Kaplan–Meier curves to display survival and hospitalization-free survival depending on
serum NGAL and cystatin C levels. The study sample was categorized according to the
75th percentile of NGAL and cystatin C: 167.5 ng/mL and 1.98 mg/L, respectively. BNP
was analyzed per 100 pg/mL increases. A Cox regression analysis was used to assessFig. 2. Kaplan–Meier estimates of survival and hospitalization-free survival according to seru
short term prognosis than the ones in the other quartiles.which variables predicted both the isolated and the combined endpoints. A
multivariate model was built based on the variables associated with the outcome in
the univariate approach. All of the analyses were conducted using SPSS 18.0 (SPSS, Inc.,
Chicago, IL). pb0.05 was considered to be statistically signiﬁcant.3. Results
Clinical characteristics of the study patients are presented in
Table 1. A comparison between those who developed the study
outcomes and those who did not are presented in Tables 1 and 2. At
90 days 27 (22.5%) patients died and 53 (44.2%) met the combined
endpoint of death or hospital admission. Patients who diedwere older
and presented higher levels of plasma BNP and serum cystatin C at
hospital admission. There was a trend for lower systolic blood
pressure measurements and higher levels of serum NGAL in this
group. Patients who met the combined endpoint of death or
hospitalization were also older, had lower GFRs and higher levels of
BNP, cystatin C and NGAL. There was a propensity for having a prior
diagnosis of Diabetes mellitus, for being under diuretics at the time of
hospital admission and for developing type 1 cardio-renal syndrome
during hospitalization.
The variables associated with a higher occurrence of death in the
univariate analysis were older age and higher levels of BNP, cystatin C
and NGAL. Patients developing type 1 cardio-renal syndrome
presented a higher risk of death, nevertheless it did not reach
statistical signiﬁcance. Similarly, the variables associated with the
occurrence of the combined endpoint of death or hospitalization were
older age, the presence of Diabetes mellitus, lower GFR, type 1
cardio-renal syndrome, BNP, cystatin C and NGAL.m cystatin C levels. Patients in the highest cystatin C quartile have a signiﬁcantly worse
Table 3
Multivariate model for prediction of all-cause death.
Death
HR (95% CI) p value
Age, per year 1.065 (1.025–1.107) 0.001
BNP, per 100 pg/mL 1.017 (1.006–1.027) 0.002
NGAL, 75th percentile vs. others 2.696 (1.203–6.041) 0.016
CRS1 0.339
Cystatin C, 75th percentile vs. others 0.771
Abbreviations: BNP, B-type natriuretic peptide; CI, conﬁdence interval; CRS1, type 1
cardio-renal syndrome; HR, hazard ratio; NGAL, neutrophil gelatinase-associated
lipocalin.
Table 4
Multivariate model for prediction of death or hospitalization.
Death or hospitalization
HR (95% CI) p value
BNP, per 100 pg/mL 1.014 (1.005–1.022) 0.002
NGAL, 75th percentile vs. others 2.860 (1.593–5.136) b0.001
Age, per year 0.153
Diabetes mellitus 0.061
GFR, per mL/min 0.360
CRS1 0.257
Cystatin C, 75th percentile vs. others 0.621
Abbreviations: BNP, B-type natriuretic peptide; CI, conﬁdence interval; GFR, glomerular
ﬁltration rate; CRS1, type 1 cardio-renal syndrome; HR, hazard ratio; NGAL, neutrophil
gelatinase-associated lipocalin.
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NGAL above the 75th percentile (167.5 ng/mL) had a signiﬁcantly
higher 3-month mortality and higher occurrence of the combined
endpoint of death or hospitalization (Fig. 1) than the patients with
lower NGAL levels. Similarly, patients with baseline serum cystatin C
above the 75th percentile (1.98 mg/L) also performed worse within
the 3-month follow-up period, weather considering the isolated or
the combined endpoint (Fig. 2).
Tables 3 and 4 show the multivariate models built. Older age and
higher levels of BNP and NGAL were independently associated with a
higher occurrence of death. Higher levels of BNP and NGAL were also
independent predictors of the occurrence of the combined outcome of
death or hospitalization. NGAL levels in the 75th percentile
(N167.5 ng/mL) were associated with a 2.7-fold increase in the
3-month risk of death and a 2.9-fold increase in the 3-month risk of
the ﬁrst occurrence of either death or hospitalization.
4. Discussion
In our study sample, serum NGAL was an independent predictor of
worse short term prognosis, namely of the occurrence of death or the
combined outcome of death or hospitalization, when measured at
admission in patients hospitalized for acute HF. Serum NGAL levels
above 167.5 ng/mL predicted an almost 3-fold increase in morbidity
and mortality within 3 months after admission for acute HF. The
interplay between heart and kidney in HF has gathered growing
interest in recent years and has been subject of intense and increasing
clinical investigation. The actual knowledge emphasizes the role of
the damaged heart signaling the kidneys through hemodynamic
factors [30]. However, it is recognized that this interaction is most
probably bidirectional. Other factors of the damaged heart contribut-
ing to kidneys damage as well as factors from the damaged kidney
acting in the heart are currently under investigation.
NGAL is a biomarker reﬂecting damage to renal tubular cells, whose
urinary and serum levels have been shown to be highly increased in
patients with acute and chronic renal injury in different stages and
settings [14,16–20,22–24,31,32]. NGAL levels rise in urine and serum as
early as from 2 h onwards after an acute insult to the kidneys [16–20],
and they can help predicting early type 1 cardio-renal syndrome
development in patients admitted with worsening HF [21].
In the present report of 121 patients with acute HF, NGAL strongly
predicted higher short term morbidity and mortality. This predictive
power was independent of other variables also associated with the
outcome, namely indexes of baseline renal function. In several previous
reports the prognostic value of WRF in acute HF has been consistently
shown and this has been truewhether renal function is evaluated based
on plasma creatinine, GFR or cystatin C [[],[]]. In our population,
although renal function, as measured by MDRD and cystatin C, showed
prognostic value in an univariate approach, in the multivariate model
built, only NGAL independently predicted worse outcome, suggesting a
role of renal injury, besides that of renal function and independent of it,
upon the beginning of acute HF episodes.Moreover, as far as we could understand from literature review,
these are the ﬁrst data on the prognostic impact of NGAL levels in an
acute HF setting, thus broadening its predictive properties beyond the
spectrum of renal disease.
Limitations of our study include the relatively small sample size
and its single-centered nature. The observational design precluded
the evaluation of the possible prognostic implications of clinical
management changes based on admission NGAL levels. This was not,
however, an objective of the study. Our results do not clarify if the
increase in NGAL results from acute kidney injury or if it is associated
with tubulo-interstitial chronic injury, as suggested by the observed
increase in urinary NGAL in chronic HF with worse outcome [26].
Nevertheless, this study was able to test our hypothesis and to detect
an independent association of increased NGAL levels with worse
outcomes in acute HF patients, suggesting a role of renal damage,
apart from renal function, in the prognosis of patients with a failing
heart. Algorithms for risk stratiﬁcation of acute HF patients would
probably be enriched if renal injury measurements, namely NGAL,
were included.
5. Conclusions
High serum NGAL independently predicts worse short term
prognosis in patients with acute HF, with levels in the highest
quartile, above 167.5 ng/mL, forecasting an almost 3-fold increase in
morbidity and mortality within 3 months after admission. These
results suggest that, in acute HF, renal injury, beyond renal function,
has a relevant role in the interaction between heart and kidney.
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